Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

1,104 questions · 1,200 findings · 23 reviews · Oral medicine and oral cancer

No studies found 143 · 11.9%GRADE not reported 760 · 63.3%Very low 201 · 16.8%Low 66 · 5.5%Moderate 29 · 2.4%High 1 · 0.1%

Low‐level laser therapy vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether electromagnetic radiation (low-level laser therapy) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

NSAIDs (ketorolac oral rinse; systemic celecoxib) vs placebo or no treatment

Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • SoF 3, Safety of the intervention over 3 months: systemic celecoxib (1 study) - 32 intervention participants reported 56 adverse effects, 20 placebo participants reported 20; 4 grade 3 events; 2 discontinued. Ketorolac…
    2 studies
    GRADE not reported

NSAIDs (ketorolac oral rinse; systemic celecoxib) vs placebo or no treatment

Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia

The review found no eligible studies for this question.

1 finding from 1 review

Antidepressants (trazodone 200 mg/day) vs placebo

Adverse event: tremor · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether antidepressants (trazodone 200 mg/day) changes adverse effects: tremor compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (systemic clonazepam 0.5 mg/day) vs placebo

Relief of burning/discomfort (symptom relief; pain intensity) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (systemic clonazepam 0.5 mg/day) changes relief of burning/discomfort (symptom relief; pain intensity) compared with placebo (very low certainty).

1 finding from 1 review

Topical bleomycin vs placebo or no treatment

Safety of the intervention (adverse effects) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    up to 3 months
    SoF 5, Safety of the intervention up to 3 months: 'All patients in the bleomycin group developed erythema with erosion by the end of the applications, whereas erythema developed in the placebo group. Discomfort was…
    1 study
    GRADE not reported

Topical treatments (benzydamine hydrochloride oral rinse) vs placebo

Adverse effects · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months) · benzydamine hydrochloride
    SoF9. Adverse effects: single study narratively reported that no adverse effects occurred from benzydamine hydrochloride oral rinse; 20 participants (1 RCT); very low.
    1 study · 20 participants
    Very low

Dietary supplements (Catuama herbal compound) vs placebo

Adverse effects: exacerbation of symptoms · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether dietary supplements (Catuama herbal compound) changes adverse effects: exacerbation of symptoms compared with placebo (very low certainty).

1 finding from 1 review

Vitamin A or retinoids (systemic or topical; incl. 13-cis-retinoic acid, acitretin) vs placebo or no treatment

Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • Interventions for treating oral leukoplakia to prevent oral cancer 2016 · Cochrane All outcomes
    4 to 12 months
    SoF 1, Clinical resolution (not completely resolved) at 4 to 12 months: 'Studies could not be combined in meta-analysis. One study evaluated topical treatment and did not find evidence of benefit; 3 studies of systemic…
    4 studies
    GRADE not reported

Dietary supplements (Catuama herbal compound) vs placebo

Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether dietary supplements (Catuama herbal compound) changes adverse effects: drowsiness compared with placebo (very low certainty).

1 finding from 1 review

Benzodiazepines (topical clonazepam) vs placebo

Somnolence · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: drowsiness compared with placebo (very low certainty).

1 finding from 1 review

Herbal extracts (tea components; Chinese herbal mixture; freeze-dried black raspberry gel) vs placebo or no treatment

Clinical resolution (oral lesion not completely resolved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • SoF 4, Clinical resolution (not completely resolved) at 3 to 6 months: '3 studies (freeze-dried black raspberry gel, green tea extract capsules, mixed tea) did not find evidence of benefit.' No GRADE. Effects text:…
    4 studies
    GRADE not reported

Benzodiazepines (topical clonazepam) vs placebo

Adverse effects: dry mouth · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms

It is very uncertain whether benzodiazepines (topical clonazepam) changes adverse effects: dry mouth compared with placebo (very low certainty).

1 finding from 1 review

Systemic beta carotene or carotenoids (incl. lycopene) vs placebo or no treatment

Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia

Systemic beta carotene or carotenoids (incl. lycopene) may leads to lower improvement of histological features (not improved) compared with placebo or no treatment (low certainty).

1 finding from 1 review

Bowman-Birk inhibitor vs placebo or no treatment

Improvement of histological features (not improved) · People with a diagnosis of oral leukoplakia
1 finding from 1 review
  • SoF 6, Histological changes: 'Not measured'. Effects text: data on histological changes from Armstrong 2013 were not available for analysis, but study authors reported no statistically significant differences in…
    1 study
    GRADE not reported

Cholinergics (bethanechol 15 mg/day) vs placebo

Adverse effects (narrative) · People with primary burning mouth syndrome (BMS), that is, oral mucosal pain with no dental or medical cause for such symptoms
1 finding from 1 review
  • Interventions for treating burning mouth syndrome 2016 · Cochrane All outcomes
    short-term (up to 3 months)
    SoF4. Adverse effects: single study narratively reported 4 participants (20%) in the bethanechol arm experienced adverse events (nausea, dizziness, blood pressure fall, cold perspiration or sporadic abdominal pain);…
    1 study · 40 participants
    Very low